SAFETY PROFILE OF NINTEDANIB IN PATIENTS WITH EFFICACY OF PIRFENIDONE IN SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE AND IDIOPATHIC PULMONARY FIBROSIS

Kristin Highland1, Oliver Distler2, Martina Gahlemann3, Arata Azuma4, Arve F. Fischer5, Maureen Mayes6, Ganesh Raghu7, Wiebe Sauter8, Mannaig Girard9, Veronika Kohlbrenner10, Emmanuelle Clerisme-Beaty11, Susanne Stowasser11, Masataka Kuwana12, Toby M Maher13, SENSIS trial investigators.1 Respiratory Institute, Cleveland Clinic, Cleveland, Ohio, United States of America; 2 Dept of Rheumatology, University Hospital Zurich, Zurich, Switzerland; 3Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland; 4 Dept of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan; 5 University of Colorado School of Medicine, Denver, Colorado, United States of America; 6 Division of Rheumatology and Clinical Immunogenetics, University of Texas MCGovern Medical School, Houston, Texas, United States of America; 7 Boehringer Ingelheim Pharma GmbH and Co KG, Biberach an der Riss, Germany; 8 Boehringer Ingelheim France S.A.S., Reims, France; 9 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, United States of America; 10 Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany; 11 Dept of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan; 12 National Heart and Lung Institute, Imperial College London, UK, and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, United Kingdom

Background: Nintedanib has been investigated in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) in the SENSIS trial and idiopathic pulmonary fibrosis (IPF) in the two INPULSIS trials. These patient populations differ in age, sex, disease characteristics and comorbidities.

Objectives: To compare the safety and tolerability of nintedanib in patients with SSc-ILD and IPF.

Methods: Adverse events that occurred over 52 weeks of treatment in the SENSIS and INPULSIS trials were assessed descriptively in subjects who received ≥1 dose of trial drug.

Results: A total of 576 subjects were treated in the SENSIS trial (288 nintedanib; 288 placebo) and 1061 in the INPULSIS trials (638 nintedanib; 423 placebo). At baseline, mean (SD) age was 54.0 (12.2) and 66.8 (8.0) years in SENSIS and INPULSIS, respectively. The proportion of males was 24.8% and 79.3%, respectively. Over 52 weeks, 19.4% and 10.8% of patients treated with nintedanib and placebo discontinued treatment in SENSIS, compared with 24.5% and 18.9% of patients treated with nintedanib and placebo in INPULSIS. Gastrointestinal adverse events were the most frequently reported adverse events with nintedanib and, as expected based on the underlying disease, were more frequent in patients with SSc-ILD than in IPF in both treatment groups (Table). Diarrhoea adverse events were reported in 75.7% and 31.6% of patients treated with nintedanib and placebo in SENSIS, and 62.4% and 18.4% of patients treated with nintedanib and placebo in INPULSIS, respectively.

Conclusion: The safety and tolerability profile of nintedanib in patients with SSc-ILD is similar to that observed in patients with IPF.


ClinicalTrials.gov number: NCT02267119

Efficacy of pirfenidone in systemic sclerosis related interstitial lung disease – a randomised controlled trial

Nupoor Acharya1, Debashish Mishra2, Sahajah Dhooria3, Vanur Dhir1, Sanjay Jain1, Shetal Khanna Sharma4, 1 Post Graduate Institute of Medical Education and Research, Chandigarh, Internal medicine, Division of Rheumatology, Chandigarh, India; 2 Post Graduate Institute of Medical Education and Research, Chandigarh, Pulmonary Medicine, Chandigarh, India

Background: Interstitial lung disease (ILD) is a major cause of morbidity and mortality in systemic sclerosis (SSc). (1) Lung fibrosis in systemic sclerosis shares immunosuppressive drugs. At the time of data cut-off, all subjects who entered OLE completed 12 months of dosing. Nineteen/20 (95%) of subjects experienced at least 1 AE, with 59 AEs occurring among the subjects during the OLE to date. The majority of AEs were mild (n = 16, 80%), with 1 severe AE (fatigue) considered unrelated to lenabasum reported. AEs occurring in ≥ 2 subjects were: dermatomyositis worsening, dizziness, fatigue, herpes zoster, nasopharyngitis, nausea, upper respiratory tract infection, and urinary tract infection. No serious AEs related to lenabasum have been reported.

Improvement was seen in multiple physician- and patient-reported efficacy outcomes; selected outcomes are presented in Figure 1. Mean (SE) changes from study start at Week 52 in the OLE were: CDASI activity score = -17.6 (SD); Patient Skin Activity VAS = -2.6 (SD); Skin29 Symptoms Domain = -21.6 (SD); Patient Itch VAS = -2.8 (SD); Physician Overall Disease VAS = -3.0 (SD); and Patient Pain VAS = -2.3 (SD). Improvements were seen in other efficacy outcomes. 12 subjects had no changes in immunosuppressive drugs during the OLE; 3 reduced chronic steroids, 2 reduced mycophenolate, 3 were switched from methotrexate to mycophenolate, 1 started methotrexate, and 1 had a burst and taper of steroids.

Figure 1. Change from Baseline in Selected Efficacy Outcomes in OLE of Phase 2 Trial JBT101-DM-001

Conclusion: Lenabasum continues to have a favorable safety and tolerability profile in the OLE of the Phase 2 trial JBT101-DM-001 with no serious AEs or study discontinuations related to lenabasum. The CDASI activity score and multiple other physician and patient-reported outcomes improved, although limitations of attributing efficacy to lenabasum in the setting of open-label dosing is acknowledged. These data support further testing of lenabasum for the treatment of DM, and a Phase 3 trial in DM has started.

similar pathogenesis as idiopathic pulmonary fibrosis. (2) Pirfenidone slows the decline in lung functions in idiopathic pulmonary fibrosis. (3) Therefore, pirfenidone may be efficacious in SSc-ILD.

Objectives: To compare the efficacy and safety of pirfenidone with placebo in SSc-ILD.

Methods: This was a double-blind, randomised, placebo controlled trial. We enrolled 34 consecutive subjects of SSc-ILD with forced vital capacity (FVC) >50% of predicted value and diffusing capacity of lung for carbon monoxide >30% of predicted value. Subjects were randomly assigned in a ratio of 1:1 to receive either pirfenidone (n = 17) or placebo (n = 17) and followed up for 6 months. Pirfenidone was started at 600 mg/day and increased to 2400 mg/day over one month and continued for the trial period. Primary outcome was to compare the proportion of patients with stabilisation or improvement in lung functions (FVC). Secondary outcome was to compare the change in FVC, Mahler's dyspnea index, 6 minute walk distance (6MWD), modified Rodnan skin score (MRSS) and change in serum levels of tumour necrosis factor α (TNF-α) and tissue growth factor β (TGF-β) at the end of 6 months. Trial was registered with clinical trials registry of India (CTR/2018/01/01449).

Results: By intention-to-treat analysis, 16 (94.1%) patients in treatment group showed stabilisation of lung function compared to 13 (76.5%) in control group (p = 0.335). The median change in FVC was -0.55% (IQR = -4.75% to 1.75%) and -1.0% (IQR = -8.5% to 5%) in the treatment and control groups respectively (p = 0.654). The median change in 6MWD was -15 (IQR = 42.5 – 13.75) meters and 0.0 (IQR = -50 – 30) meters in treatment and control groups respectively (p = 0.601). The median of focial scores for transitional dyspnea index in both the treatment and control groups were 3.0 (IQR = 0 – 3) (p = 0.838). Median change in MRSS was 0.0 (IQR = -2.0 –1.0) and -1.0 (IQR = -4.0 – 0.0) in treatment and control groups (p = 0.828). Difference in TNF-α levels were -5.14 (IQR = -14.6 –0.29) pg/ml in the treatment and -2.94 (IQR = -5.1 – -2.35) pg/ml control group (p = 0.918). Difference in TGF-β levels in treatment and control groups were -186.73 (IQR = -731.43 –64.6) pg/ml and 24.29 (IQR = 233.21 – 362.0) pg/ml respectively (p = 0.093). The mean tolerated dose of pirfenidone was 1700 ± 564 mg/day. Adverse events were mild, most common among them were gastrointestinal followed by skin rashes. Only one serious gastrointestinal adverse effect was documented.

Conclusion: We failed to demonstrate a beneficial effect of pirfenidone over placebo in stabilising FVC, functional status, or skin disease after 6 months of therapy. A larger study with longer follow up period may be further required.

REFERENCES:

Acknowledgement: Study drug and placebo was provided by CIPLA Ltd. Disclosure of Interests: None declared. DOI: 10.1136/annrheumdis-2019-eular.5921

OP0244

EFFICACY AND SAFETY OF LOW-DOSE IL-2 IN PATIENTS WITH MULTIPLE MYOSITIS/DERMATOMYOSITIS

He-Hua Sun1, Sheng-xiao Zhang2, Jia Wang3, Yu-Fei Hao1, Guang-Ying Liu1, Caihong Wang1, Chong Gao2, Li Xiao-Feng4. 1The Second Hospital of Shaxi Medical University, Department of Rheumatology, Taiyuan, China; 2Brigham and Women’s Hospital, Harvard Medical School, Department of Pathology, Boston, United States of America

Background: Dermatomyositis (DM) and polymyositis (PM) are rare chronic-inflammatory disorders with significant associated morbidity and mortality despite treatment (1-2), characterized by subacute onset of proximal muscle weakness, elevated muscle enzymes, and inflammatory infiltrates on a muscle biopsy. Although several hypotheses have been proposed for triggers of inflammation in the diseases (3), growing evidences have focused on the immune disorders (4). However, the quantitative changes of lymphocyte subsets in DM/PM are unclear and whether low-dose IL-2 could rebalance the lymphocyte subsets and further benefit to remission disease activity of DM/PM patients is unknown.

Objectives: To investigate the quantitative status of peripheral blood lymphocyte subsets in the patients for the exploration of pathogenesis and evaluate the safety and efficacy of low-dose IL-2 therapy in patients with DM/PM.

Methods: From February 2016 to October 2018, total 147 patients with PM/DM and 128 gender and age matched healthy individuals were enrolled in this study. The absolute numbers of T, B, NK, CD4+ T, CD8+ T, Th1, Th2, Th17 and Treg cells in peripheral blood of these individuals were detected by flow cytometry combined with standard absolute counting beads. Patients in IL-2 group (n=31) were not only given traditional treatments, but injected subcutaneously human IL-2 (aldesleukin) at 50 WIU per day for a 5-day course. The demographic features, clinical manifestations and laboratory indicators were compared before and after the treatment.

Results: Patients with PM/DM had lower levels of Treg cells as well as T, CD4+ T, CD8+ T, Th1, Th2, and Th17 compared with those of the healthy controls (P < 0.05), which was correlated with disease activity(P < 0.05). After IL-2 administration, the absolute numbers of peripheral lymphocyte subsets in patients were significantly increased (P < 0.05), leading to a better remission compared with the patients received conventional therapy (P < 0.05).

REFERENCES: